<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><?origin nihpa?><?iso-abbr Pharmacogenomics J.?><?submitter-system nihms?><?submitter-canonical-name Nature Publishing Group?><?submitter-canonical-id NATURE-STRUCTUR?><?submitter-userid 8068858?><?submitter-authority myNCBI?><?submitter-login nature-structure?><?submitter-name Nature Publishing Group?><?domain nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101083949</journal-id><journal-id journal-id-type="pubmed-jr-id">22416</journal-id><journal-id journal-id-type="nlm-ta">Pharmacogenomics J</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacogenomics J.</journal-id><journal-title-group><journal-title>The pharmacogenomics journal</journal-title></journal-title-group><issn pub-type="ppub">1470-269X</issn><issn pub-type="epub">1473-1150</issn></journal-meta><article-meta><article-id pub-id-type="pmcid">4980276</article-id><article-id pub-id-type="pmid">26856248</article-id><article-id pub-id-type="doi">10.1038/tpj.2015.93</article-id><article-id pub-id-type="manuscript">nihpa738441</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chhibber</surname><given-names>Aparna</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>French</surname><given-names>Courtney E.</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="A2">2</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Yee</surname><given-names>Sook Wah</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Gamazon</surname><given-names>Eric R.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A13">13</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Theusch</surname><given-names>Elizabeth</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Xiang</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Webb</surname><given-names>Amy</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Papp</surname><given-names>Audrey C.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ann</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Simmons</surname><given-names>Christine Q.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Konkashbaev</surname><given-names>Anuar</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chaudhry</surname><given-names>Amarjit S.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Mitchel</surname><given-names>Katrina</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Stryke</surname><given-names>Doug</given-names></name><degrees>BA</degrees><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Ferrin</surname><given-names>Thomas E.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Weiss</surname><given-names>Scott T.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kroetz</surname><given-names>Deanna L.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sadee</surname><given-names>Wolfgang</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Nickerson</surname><given-names>Deborah A.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Krauss</surname><given-names>Ronald M.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Alfred L.</given-names><suffix>Jr.</suffix></name><degrees>MD</degrees><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Schuetz</surname><given-names>Erin G.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Medina</surname><given-names>Marisa W.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cox</surname><given-names>Nancy J.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Scherer</surname><given-names>Steven E.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A5">5</xref><xref rid="FN1" ref-type="author-notes">**</xref></contrib><contrib contrib-type="author"><name><surname>Giacomini</surname><given-names>Kathleen M.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref><xref rid="FN1" ref-type="author-notes">**</xref></contrib><contrib contrib-type="author"><name><surname>Brenner</surname><given-names>Steven E</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A2">2</xref><xref rid="FN1" ref-type="author-notes">**</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA</aff><aff id="A2"><label>2</label>Departments of Molecular and Cell Biology and Plant and Microbial Biology, University of California, Berkeley</aff><aff id="A3"><label>3</label>Division of Genetic Medicine, Department of Medicine, Vanderbilt University, Nashville, Tennessee</aff><aff id="A4"><label>4</label>Children&#x02019;s Hospital Oakland Research Institute, Oakland, CA</aff><aff id="A5"><label>5</label>Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA</aff><aff id="A6"><label>6</label>Department of Biomedical Informatics, Program in Pharmacogenomics; College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH</aff><aff id="A7"><label>7</label>Department of Pharmacology, Program in Pharmacogenomics; College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH</aff><aff id="A8"><label>8</label>Department of Pharmaceutical Sciences, St. Jude Children&#x02019;s Research Hospital, Memphis, TN</aff><aff id="A9"><label>9</label>Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California</aff><aff id="A10"><label>10</label>Channing Division of Network Medicine, Department of Medicine, Brigham and Women&#x02019;s Hospital, Boston, MA</aff><aff id="A11"><label>11</label>Department of Genome Sciences, University of Washington, Seattle, WA</aff><aff id="A12"><label>12</label>Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff><aff id="A13"><label>13</label>Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands</aff><author-notes><corresp id="FN1"><label>**</label>Corresponding Authors: Steven Brenner: <email>brenner@compbio.berkeley.edu</email>, Kathy Giacomini: <email>kathy.giacomini@ucsf.edu</email>, 1550 4<sup>th</sup> St, Mission Bay, RH 581, Sa Francisco, CA 94143, Tel: (415) 514-4363, Fax: (415) 514-4361, Steven Scherer: <email>sscherer@bcm.edu</email></corresp><fn id="FN2"><label>*</label><p>Co-first Authors</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>18</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>09</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>8</month><year>2016</year></pub-date><elocation-id>10.1038/tpj.2015.93</elocation-id><permissions><license><license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:
<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p></license></permissions><abstract><p id="P1">Variation in the expression level and activity of genes involved in drug disposition and action (&#x0201c;pharmacogenes&#x0201d;) can affect drug response and toxicity, especially when in tissues of pharmacological importance. Previous studies have relied primarily on microarrays to understand gene expression differences, or have focused on a single tissue or small number of samples. The goal of this study was to use RNA-seq to determine the expression levels and alternative splicing of 389 PGRN pharmacogenes across four tissues (liver, kidney, heart and adipose) and lymphoblastoid cell lines (LCLs), which are used widely in pharmacogenomics studies. Analysis of RNA-seq data from 139 different individuals across the 5 tissues (20&#x02013;45 individuals per tissue type) revealed substantial variation in both expression levels and splicing across samples and tissue types. This in-depth exploration also revealed 183 splicing events in pharmacogenes that were previously not annotated. Overall, this study serves as a rich resource for the research community to inform biomarker and drug discovery and use.</p></abstract><kwd-group><kwd>RNA-seq</kwd><kwd>Pharmacogenes</kwd><kwd>Splicing</kwd><kwd>Biomarkers</kwd><kwd>JuncBASE</kwd><kwd>Pharmacogenomics of Research Network</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p id="P2">Variation in the expression levels and splicing of drug metabolizing enzymes, transporters, and targets, such as receptors and ion channels, has been associated with inter-individual differences in optimal drug dose, drug efficacy, and adverse drug events <sup><xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref></sup>. Thus, a comprehensive study of variation in the transcriptome profiles of pharmacologically relevant tissues promises to yield important insights into the molecular basis of variation in drug response. Technological advances in quantifying the transcriptome and the rapid development of high-throughput screening methodologies have led to the identification and characterization of many biomarkers of drug response <sup><xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref></sup>. These innovations have transformed the way we design and analyze pharmacogenomics studies and are increasingly informing development of approaches to clinical practice.</p><p id="P3">Transcriptome sequencing, or RNA-Seq, is facilitating analyses at the transcript level with an unprecedented resolution. As the technology has developed, longer reads and higher throughput have allowed for detailed evaluation of whole transcriptomes across many samples <sup><xref rid="R5" ref-type="bibr">5</xref></sup>. Analytical approaches have emerged, including Cufflinks <sup><xref rid="R6" ref-type="bibr">6</xref></sup> and DESeq <sup><xref rid="R7" ref-type="bibr">7</xref></sup> for gene expression analysis and DEXSeq <sup><xref rid="R8" ref-type="bibr">8</xref></sup>, MISO <sup><xref rid="R9" ref-type="bibr">9</xref></sup>, and JuncBASE <sup><xref rid="R10" ref-type="bibr">10</xref></sup> for splicing analysis. However, the use of next-generation sequencing technology for pharmacogenomics research has been limited <sup><xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R11" ref-type="bibr">11</xref></sup>. Although community-wide efforts such as GTEx <sup><xref rid="R12" ref-type="bibr">12</xref></sup> are facilitating studies of expression quantitative trait loci (eQTLs), there has not been an application of RNA-Seq to large sample sets across diverse human tissues with a focus on genes involved in drug disposition and tissues of greater pharmacological relevance and action.</p><p id="P4">In pharmacogenomics, polymorphisms that affect expression levels or result in alternative splicing of drug metabolizing enzymes are known to have large effects on drug disposition and response. For example, UGT1A1*28 (rs8175347), with seven thymine-adenine <sup><xref rid="R13" ref-type="bibr">13</xref></sup> repeats in the promoter region, leads to reduced transcription rates of this enzyme and profound toxicity in patients receiving the topoisomerase inhibitor, irinotecan <sup><xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref></sup>. Likewise, alternative splicing of <italic>CYP2D6</italic> occurs frequently in human populations and is responsible for reduced activity of the enzyme <sup><xref rid="R16" ref-type="bibr">16</xref></sup>. Given these large and clinically important effects in drug metabolizing enzymes, a systematic study of the transcriptome with a focus on pharmacogenes is clearly needed. While several research groups have performed transcriptome profiling and alternative splicing event analyses in human cell lines and tissues <sup><xref rid="R17" ref-type="bibr">17</xref>&#x02013;<xref rid="R19" ref-type="bibr">19</xref></sup>, these studies are limited to single-tissue types or use pooled samples. Thus, information about inter-individual variation in gene expression and splicing from a given tissue type or inter-tissue variation is limited, despite the value of such studies in identifying biomarkers for differential drug response or toxicity.</p><p id="P5">Given these limitations, the NIH-supported Pharmacogenomics Research Network (PGRN) initiated a transcriptome sequencing project to catalog variation in gene expression and splicing across individuals in tissues and genes of pharmacologic importance. Tissues studied include liver, a key organ for drug metabolism <sup><xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref></sup>, kidney, the site of excretion for many drugs <sup><xref rid="R22" ref-type="bibr">22</xref></sup>, as well as heart and adipose tissue, where pharmacogenes can affect local drug distribution and action <sup><xref rid="R23" ref-type="bibr">23</xref></sup>. Lymphoblastoid cell lines were also included, as they have been widely used as a cell-based model for a variety of pharmacogenomics studies <sup><xref rid="R24" ref-type="bibr">24</xref>&#x02013;<xref rid="R26" ref-type="bibr">26</xref></sup>. In this article, we characterized the variability in the expression and splicing of 389 PGRN pharmacogenes across individuals and between four human tissue types and lymphoblastoid cell lines, and identified novel alternative splicing events in these samples. Further, we provide this information for community use, in the form of expression and splicing profiles for 139 individuals. This resource will be valuable for future pharmacogenomics studies as both a discovery and validation platform.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S3"><title>Selection of Pharmacogenes</title><p id="P6">Protein coding genes were defined as those with a start codon in the Gencode v12 <sup><xref rid="R13" ref-type="bibr">13</xref></sup> annotation. A subset of these was defined as &#x0201c;PGRN pharmacogenes.&#x0201d; Our list of 389 pharmacogenes was compiled from PharmGKB<sup><xref rid="R27" ref-type="bibr">27</xref></sup>, a curated knowledgebase about the impact of genetic variation on drug response, PharmaADME <sup><xref rid="R28" ref-type="bibr">28</xref></sup>, the U.S. Food and Drug Administration (FDA) Pharmacogenomics Biomarkers <sup><xref rid="R29" ref-type="bibr">29</xref></sup> and the literature <sup><xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R30" ref-type="bibr">30</xref>&#x02013;<xref rid="R33" ref-type="bibr">33</xref></sup>. Genes that are annotated in at least two of these resources or publications were selected as PGRN pharmacogenes. These include 160 enzymes, 84 transporters, 15 ion-channels, 27 receptors, 24 nuclear receptors and other transcription factors, as well as 22 other genes, including G-protein coupled receptors that are drug targets and play an important role in drug disposition, response, or toxicity (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>).</p></sec><sec id="S4"><title>Tissues Collection, RNA Isolation, and Preparation of RNA-sequencing Library</title><p id="P7">Tissue from 24 liver, 20 kidney (cortex), 25 heart (left ventricle), 25 adipose (subcutaneous) samples, and 45 lymphoblastoid cell lines (LCLs) were obtained from PGRN research groups: the Pharmacogenomics of Anticancer Agents Research in Children (PAAR4Kids) provided liver tissues, Pharmacogenomics of Membrane Transporters (PMT) provided kidney samples, Pharmacogenomics and Risk of Cardiovascular Disease (PARC) provided adipose tissue and lymphoblastoid cell lines, and Pharmacogenomics of Arrhythmia Therapy (PAT) provided heart tissue. Demographic information on the samples is described in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table S2</xref>.</p><p id="P8">Total RNA was extracted for each sample, selected for mRNA by poly-A selection, and then fragmented to a mean length of ~120&#x02013;180 base pairs. Strand-specific cDNA libraries were prepared and sequenced on an Illumina HiSeq 2000 at depths of 45&#x02013;171 million paired end 100bp reads per sample.</p></sec><sec id="S5"><title>Alignment and Transcriptome Analysis</title><p id="P9">Raw reads were mapped to the human genome sequence (hg19) <sup><xref rid="R34" ref-type="bibr">34</xref></sup> using Tophat v2.0.6 <sup><xref rid="R35" ref-type="bibr">35</xref></sup> and PCR duplicates were removed. Some samples had a low percentage of unique reads likely due to limited starting material. Transcript structure assembly was performed with Cufflinks (v.2.0.2) <sup><xref rid="R6" ref-type="bibr">6</xref></sup> on each sample for each tissue type. To control for differing sequencing depths between tissue types, and the variable number of samples analyzed for each tissue type, gene expression analysis was performed on a subset of the data: 20 million reads per sample and 18 samples per tissue type. Gene expression values (in Fragments per Kilobase of Exon Mapped, FPKM) were calculated by summing per-isoform FPKM values generated by Cuffdiff (v2.2.1) <sup><xref rid="R6" ref-type="bibr">6</xref></sup> for each sample or by tissue type. Throughout, gene estimates are used unless isoforms are specifically mentioned.</p><p id="P10">To discover novel splice events and analyze differential splicing, the subsampled reads were run through the JuncBASE v0.6 <sup><xref rid="R10" ref-type="bibr">10</xref></sup> pipeline. JuncBASE uses junction reads from an RNA-Seq experiment to calculate inclusion and exclusion of individual splicing events. These are measured as percent spliced in (PSI). Such measures are generally more reliable than isoform reconstruction as they require less inference.</p></sec><sec id="S6"><title>Validation</title><p id="P11">To validate selected splice events that were not found in the gene annotations, we created primers specific to the novel event and looked for amplification by PCR using pooled liver cDNA. (<xref rid="SD2" ref-type="supplementary-material">Supplemental Figure S1</xref>). To validate the PSI estimates derived from RNA-seq, PSI values for two common and previously annotated splice variants in <italic>HMGCR13(&#x02212;)</italic>
<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and <italic>LDLR4(&#x02212;)</italic>
<sup><xref rid="R13" ref-type="bibr">13</xref></sup><italic>,</italic> were quantified by qPCR in LCLs (n=39) from the same RNA that was used to prepare the RNA-seq libraries. The PSI values for these two events in LCLs calculated by qPCR and RNA-seq were positively correlated with R<sup>2</sup> values of 0.43 and 0.5 (<xref rid="SD2" ref-type="supplementary-material">Supplemental Figure S2</xref>).</p><p id="P12">To validate the patterns of pharmacogene expression and splicing identified in this study, we analyzed data from the Genotype Tissue Expression (GTEx) Project (v4)<sup><xref rid="R36" ref-type="bibr">36</xref></sup>. Expression (RPKM, mapped reads per kilobase per million mapped reads) values per individual, per gene were downloaded from the GTEx portal (<ext-link ext-link-type="uri" xlink:href="http://gtexportal.org">http://gtexportal.org</ext-link>) to study variability in gene expression and patterns of expression across tissues. Aligned reads were downloaded from SRA/dbGaP and run through the JuncBASE pipeline in the same way as was done for the PGRN data to compare differential splicing patterns between the two datasets and novel junctions identified in the PGRN dataset.</p><p id="P13">Further details regarding all methodology are included in the <xref rid="SD1" ref-type="supplementary-material">supplemental methods</xref>.</p></sec></sec><sec sec-type="results" id="S7"><title>Results</title><sec id="S8"><title>The Pharmacogenomics Research Network RNA-Seq Project</title><p id="P14">The Pharmacogenomics Research Network (PGRN) RNA-Seq project was designed to provide in-depth investigation of the transcriptomes of pharmacologically relevant human tissues with a focus on genes of particular interest to the pharmacogenomics community (<xref rid="F1" ref-type="fig">Figure 1</xref>). In order to study inter-individual variability in expression and splicing of PGRN pharmacogenes (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S1</xref>), we generated transcriptome data from 24 liver, 20 kidney, 25 heart, and 25 adipose samples and 45 LCLs (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S2</xref>). For each sample, reads were mapped to the human genome <sup><xref rid="R35" ref-type="bibr">35</xref></sup>, resulting in 10 to 97 million mapped reads per sample. To control for this substantial difference in sequencing depth and sample number between tissues, 18 samples for each tissue were selected and subsampled down to 20 million reads/sample for further expression and splicing analyses, resulting in a total of 90 samples. Gene expression and splicing results are available for download (<ext-link ext-link-type="uri" xlink:href="http://pharmacogenetics.ucsf.edu/expression/rnaseqdata.html">http://pharmacogenetics.ucsf.edu/expression/rnaseqdata.html</ext-link>, GSE70503 <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=kvsleaoqfnittwr&#x00026;acc=GSE70503">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=kvsleaoqfnittwr&#x00026;acc=GSE70503</ext-link>), and reads are deposited in the Sequence Read Archive (SRP060355). The expression profiles of all pharmacogenes across tissues and individuals is included in <xref rid="SD2" ref-type="supplementary-material">Supplemental Figure S3</xref>. A brief overview of alternative splicing and gene expression of all protein coding genes can be found in the <xref rid="SD1" ref-type="supplementary-material">supplemental results</xref>.</p></sec><sec id="S9" sec-type="methods"><title>Analysis of PGRN pharmacogene gene expression</title><p id="P15">We found that 161 (of 389) of our PGRN pharmacogenes were expressed at FPKM &#x02265; 1 in at least one sample across all five tissue types in our data set and 87 pharmacogenes were expressed at FPKM &#x02265;1 in all samples of all five tissue types (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S3A</xref>). As a group, PGRN pharmacogenes were significantly enriched for variable gene expression between individuals, and were among the top ten most variably expressed gene sets (classified by gene ontology biological process <sup><xref rid="R37" ref-type="bibr">37</xref></sup>) in the physiological tissues (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S4</xref>). We also observed subsets of pharmacogenes that showed similar patterns of expression across the different tissues (k-means clustering of gene expression of 389 pharmacogenes, <xref rid="F2" ref-type="fig">Figure 2A</xref>). For example, some pharmacogenes were expressed consistently at low levels across all tissues and samples (e.g. ABCC12 and ESR2, <xref rid="F2" ref-type="fig">Figure 2B</xref>). In contrast, 11 pharmacogenes were very highly expressed, though to different levels, across all tissues and LCLs (<xref rid="F2" ref-type="fig">Figure 2C</xref>); these include genes involved in mitochondrial structure or function (<italic>ADH5</italic>, <italic>ALDH2</italic>, <italic>CYB5R3</italic>, <italic>SOD2</italic>) and glutathione transferase activity (<italic>GSTK1</italic>, <italic>GSTO1, GSTP1</italic>) <sup><xref rid="R37" ref-type="bibr">37</xref></sup>.</p><p id="P16">Not surprisingly, PGRN pharmacogenes are generally more highly expressed in liver compared to the other tissues (<xref rid="SD2" ref-type="supplementary-material">Supplemental Figure S4</xref>). Many genes coding for xenobiotic metabolizing enzymes and transporters were highly and specifically expressed in the liver, an organ important for drug metabolism (<xref rid="F2" ref-type="fig">Figure 2D</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplemental Table S5A</xref>). Pharmacogenes expressed at highest abundance in the kidney, the major organ for secretion and reabsorption, include a number of solute carrier transporters (SLC genes) (<xref rid="F2" ref-type="fig">Figure 2E</xref>), which play important roles in drug secretion or reabsorption <sup><xref rid="R38" ref-type="bibr">38</xref></sup>, as well as enzymes such as <italic>ABP1</italic> and <italic>FMO1</italic>. In addition, pharmacogene expression levels in the liver and kidney varied greatly among individuals. For example, the expression levels of a number of CYPs in the liver and SLC transporters in the kidney varied by over 100-fold and 1000-fold respectively (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p><p id="P17">The list of PGRN pharmacogenes included 119 (out of 389) genes that are currently drug targets or are under clinical development as potential targets for various diseases <sup><xref rid="R39" ref-type="bibr">39</xref></sup>. These drug target genes may be expressed abundantly in tissues not primarily involved in drug disposition. For example, a small number of pharmacogenes were highly expressed solely in the heart (<xref rid="F2" ref-type="fig">Figure 2F</xref>). These genes are all involved with cardiac contractility and include, for example, ion channels involved in cardiac conductance (<italic>SCN5A</italic>, <italic>CACNA1C</italic>, <italic>KCNH2</italic>) that are targeted by many drugs <sup><xref rid="R40" ref-type="bibr">40</xref>&#x02013;<xref rid="R42" ref-type="bibr">42</xref></sup>. Most pharmacogenes expressed (FPKM &#x02265; 1) in adipose tissue were expressed in other tissues as well (<xref rid="F2" ref-type="fig">Figure 2A</xref>). The strongest correlation of pharmacogene expression profiles among tissues were detected between adipose and heart (r=0.83), as is true for all protein-coding genes expression between adipose and heart (r=0.90) (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S6</xref>).</p><p id="P18">Compared to the four physiological tissues, LCLs showed lower overall expression levels of pharmacogenes: proportionally fewer pharmacogenes were expressed in at least one LCL sample or expressed in all LCL samples compared to all protein-coding genes (chi-square test: 48% vs. 64%, p&#x0003c;0.0001 and 30% vs. 48%, p&#x0003c;0.0001 in at least one sample or all samples respectively, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref>). Pharmacogenes expressed at lower levels in LCLs than in the tissues assayed include genes important for drug disposition - for example, genes coding for enzymes (cytochrome P450s, UGTs, SULTs), SLC transporters, ion channels and receptors (<xref rid="SD1" ref-type="supplementary-material">Supplemental Table S5B</xref>).</p></sec><sec id="S10" sec-type="methods"><title>Analysis of PGRN pharmacogene splicing</title><p id="P19">We found that 278 of the 389 pharmacogenes (72%) showed clear evidence of being alternatively spliced (&#x02265; 2 isoforms) in our data set. Receptor and channel genes are the least alternatively spliced (&#x0003c;50%, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table S7</xref>), although, likely due to the small numbers of genes, only receptors are significantly depleted (Bonferroni-corrected p&#x0003c;0.05, hypergeometric test). Another 66 pharmacogenes had inconclusive evidence of being alternatively spliced either because the alternative splice event is very rare, or because of low gene expression. The other 45 pharmacogenes are substantially expressed (FPKM&#x0003e;10) in at least one sample but have no evidence of alternative splice events in this dataset.</p><p id="P20">Differential alternative splicing between pairs of tissues was evident for 30&#x02013;70% of PGRN pharmacogenes tested (Wilcoxon test, FDR&#x0003c;0.05) (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table S8</xref>), with LCLs showing the greatest differences in splicing events compared with the other tissues. We also found dozens of inferred splice events that were only observed in one of our five tissue types, often because the gene was not expressed in other tissues but also possibly because only alternative splice events were used in those tissue types (<xref rid="F4" ref-type="fig">Figure 4A</xref>). When we control for gene expression differences between tissues by requiring the potentially alternatively spliced region to have high total read coverage in a number of samples for the four other tissues, we see only a very small fraction of genes (0&#x02013;5%) have tissue-specific splice events (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table S9</xref>).</p><p id="P21">Notably, a total of 183 alternative splicing events (in 102 out of 389 genes) included splice junctions not previously annotated, but which were present with a robust coverage of at least 5 reads/100bp in at least one sample (<xref rid="F4" ref-type="fig">Figure 4B</xref>). The greatest number of previously non-annotated pharmacogene splicing events was observed in the liver samples, likely because many of those genes are very highly expressed in that tissue, making it easier to observe these often low expressed events. One of the novel splicing events observed in liver was an alternative last exon of <italic>SLC22A7</italic>, a gene that encodes a transporter of endogenous compounds and prescription drugs (<xref rid="F4" ref-type="fig">Figure 4C</xref>). This newly found alternative event was validated by PCR (<xref rid="SD2" ref-type="supplementary-material">Supplemental Figure S1</xref>), is predicted to produce a protein with a truncated C-terminus, and was substantially and variably expressed in the liver samples. A novel splicing event observed in heart was in <italic>SCN5A</italic>, a gene encoding a sodium channel important in maintaining normal cardiac rhythm (<xref rid="F4" ref-type="fig">Figure 4D</xref>). Observed in three heart samples, this novel alternative 3&#x02032; splice site in exon 23 excludes 83 bases and generates a downstream premature termination codon that is expected to cause the transcript to be degraded by the nonsense-mediated mRNA decay pathway.</p></sec></sec><sec sec-type="discussion" id="S11"><title>Discussion</title><p id="P22">Over the last several years, there have been many studies using RNA-Seq to quantify gene expression and to identify novel alternative splicing events in many tissue and cell types <sup><xref rid="R43" ref-type="bibr">43</xref>&#x02013;<xref rid="R48" ref-type="bibr">48</xref></sup>. Here, we applied this approach to characterize the expression of 389 genes of pharmacologic importance (genes involved in drug disposition, response or toxicity) in multiple human tissue types and LCLs. Unlike many other transcriptome profiling studies using RNA-Seq, this report presents findings for multiple samples across tissues, allowing the capture of inter-individual variation in expression levels in addition to comparison of expression and splicing across different tissues. Further, results in multiple subjects act as biological replicates for a given tissue type, allowing for a more accurate representation of tissue-specific splicing and expression. By incorporating inter-individual variation in our study of several human tissues, our data represent an important addition to our understanding of human transcriptomics. This dataset is available at <ext-link ext-link-type="uri" xlink:href="http://pharmacogenetics.ucsf.edu/expression/rnaseqdata.html">http://pharmacogenetics.ucsf.edu/expression/rnaseqdata.html</ext-link>.</p><p id="P23">In comparing global analyses of protein-coding and pharmacogene expression, we observed several interesting patterns. Prominently, the majority of PGRN pharmacogenes were expressed at lower levels in LCLs compared to the four physiological tissues studied, in contrast to expression levels across all protein coding genes. As an actively and aggressively proliferating cell type, gene expression in LCLs is tuned to growth, and thus relative expression of genes involved in other cellular processes may be suppressed. Further, it is possible that peripheral B-lymphocytes, the primary cells from which LCLs are derived, also show significantly different patterns of expression from the other four physiological tissues included in this study. These results suggest that consideration of the phenotype and gene of interest is important when using LCLs as a proxy for other tissues in pharmacogenetic studies, as well as when using tissues as proxies for each other. Overall, more pharmacogenes were expressed at higher levels in the liver compared to other tissues. While this result is not unexpected given the importance of the liver in drug metabolism and transport and the bias towards liver-specific genes in the field of pharmacogenomics, it also demonstrates the importance of conducting studies in samples of the relevant tissue type where possible. We also observed high correlation in gene expression values between adipose and heart tissues among both protein coding genes and the subset of PGRN pharmacogenes. This result is consistent with the finding that adipose derived stem cells have been shown to spontaneously differentiate into cardiomyocytes and that both adipose and cardiac tissues derive from the mesoderm <sup><xref rid="R49" ref-type="bibr">49</xref>, <xref rid="R50" ref-type="bibr">50</xref></sup>.</p><p id="P24">We also observed interesting patterns of alternative splicing in this study, including the discovery of splicing events not previously annotated and significant differential splicing between LCLs and other tissue types. Since splicing detection is dependent on sequencing coverage and the number of samples analyzed, we investigated the effects of subsampling down the number of reads and samples to make them equivalent between tissues (<xref rid="SD1" ref-type="supplementary-material">Supplementary Results</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Figure S6</xref>). Using only 18 samples per tissue, we were still able to detect 95% of splice events we would be able to observe with all samples in our data set. Subsampling the reads limits the detection of rare splicing events which particularly affects novel splice events, as they generally have low PSI values and, thus, low read coverage (<xref rid="SD2" ref-type="supplementary-material">Supplementary Figure S7</xref>), or occur in only a small number of samples. As rare splice events may represent physiologically relevant alternative splicing, the splicing results from using all of our data (all reads, all samples) are also available to download.</p><p id="P25">Among the splicing events identified, we observe both previously characterized as well as novel alternative splicing events. For example, an alternative 3&#x02032; splice site in the drug target <italic>SCN5A</italic> generates a premature termination codon predicted to trigger the nonsense-mediated mRNA decay pathway (NMD). <italic>SCN5A</italic> encodes the main cardiac voltage-gated sodium channel important in maintaining normal cardiac conduction. A number of drugs target sodium channels, including antiarrhythmics and non-antiarrhythmic sodium channel blockers. Changes in structure, activity, and expression of drug targets, such as that encoded by SCN5A, can alter the efficacy of drugs designed to target these proteins <sup><xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R52" ref-type="bibr">52</xref></sup>. This event may be indicative of a novel role for alternative splicing coupled with NMD in the regulation of this gene <sup><xref rid="R53" ref-type="bibr">53</xref></sup>. Additionally, a novel truncated isoform of the transporter <italic>SLC22A7</italic> was identified. The gene <italic>SLC22A7</italic> is expressed in both kidney and liver and is important for transport of endogenous compounds <sup><xref rid="R54" ref-type="bibr">54</xref></sup> and a number of prescription drugs <sup><xref rid="R55" ref-type="bibr">55</xref>&#x02013;<xref rid="R57" ref-type="bibr">57</xref></sup>.</p><p id="P26">We also observed substantial variability in gene expression, particularly among drug transporters and drug metabolizing enzymes. In the liver, several cytochrome P450 (CYP) enzymes showed significant variability in expression levels between individuals; such variability can drive differences in drug metabolism across individuals, leading to variation in drug efficacy and susceptibility to toxicity <sup><xref rid="R58" ref-type="bibr">58</xref></sup>. One example includes CYP3A4, which is responsible for activation and deactivation of a number of drugs by oxidation in the liver. Induction of CYP3A4 by concomitant medications or dietary supplements is well-established, and is considered a major source of variation in drug response <sup><xref rid="R59" ref-type="bibr">59</xref></sup>. The enormous inter-individual variation in the expression levels of CYP3A4 we observe in the liver samples may be due to differences in diet, including dietary supplements, or medications among the individuals, in addition to genetic variation. Like drug metabolism, renal elimination of drugs is also variable across individuals in part due to variation in renal secretion and reabsorption; this variation can be driven by differences in expression levels of renal transporters across individuals. We observed profound differences in the expression levels of renal secretory and reabsorptive transporters, particularly the solute carrier transporters (SLCs). For example, expression of the uric acid transporter <italic>SLC22A12</italic> varied almost 1000-fold between individuals in the kidney (<xref rid="F3" ref-type="fig">Figure 3</xref>). As a target for drugs that treat hyperuricemia <sup><xref rid="R60" ref-type="bibr">60</xref></sup>, the expression level of <italic>SLC22A12</italic> could be an important determinant of drug response.</p><p id="P27">As is true of any study using human organs, while only healthy tissues were used for mRNA extraction, the patients themselves may have had a disease affecting other organs or may have been taking medications. In particular for the study of pharmacogenes, the variability in xenobiotic exposure is a concern, as such exposure is known to alter pharmacogene expression <sup><xref rid="R61" ref-type="bibr">61</xref>, <xref rid="R62" ref-type="bibr">62</xref></sup> and splicing <sup><xref rid="R63" ref-type="bibr">63</xref>&#x02013;<xref rid="R67" ref-type="bibr">67</xref></sup> profiles. The fact that the variability in splicing and expression both within and between tissues was similar to that identified in an alternate dataset with different samples suggests that the patterns of splicing and expression detected are not driven by a single overrepresented disease, phenotype, or environmental exposure in our dataset; however, in both datasets the variability detected may be driven in part by differences in health status or exposures between individuals. Patient age and sex can also explain a portion of variability in gene expression <sup><xref rid="R68" ref-type="bibr">68</xref>, <xref rid="R69" ref-type="bibr">69</xref></sup>; for example, a few pharmacogenes appeared to show higher expression levels in samples from pediatric patients. Given the small sample sizes and skewed sex and age distributions in some of the tissue types, this study was not optimal for investigating variation due to these two factors. Finally, other potential sources of variability in our dataset include subtle differences in cellular composition of the tissue samples or sample collection protocols.</p><p id="P28">Pharmacogenomic studies have largely focused on the effects of genetic polymorphisms in pharmacogenes on drug response and drug toxicity <sup><xref rid="R70" ref-type="bibr">70</xref>, <xref rid="R71" ref-type="bibr">71</xref></sup>. Our data suggest that genes involved in drug disposition and toxicity can be variably spliced and expressed among individuals and across tissues. Further, given that splicing can affect expression, localization, and function of genes <sup><xref rid="R72" ref-type="bibr">72</xref>, <xref rid="R73" ref-type="bibr">73</xref></sup>, our results suggest that splicing may be a relatively unexplored source of variability in drug response, toxicity, and efficacy. Transcriptome profiling (including both expression and splicing) of pharmacogenes may be a valuable tool for identification of mechanisms and possible prediction of this variability. As the first in depth analysis of transcript structure and expression of genes that play a key role in drug disposition, this PGRN RNAseq resource will be valuable for biomarker and drug target discovery and validation.</p></sec><sec sec-type="supplementary-material" id="S12"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>1</label><media xlink:href="NIHMS738441-supplement-1.pdf" orientation="portrait" xlink:type="simple" id="d37e1006" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>2</label><media xlink:href="NIHMS738441-supplement-2.pdf" orientation="portrait" xlink:type="simple" id="d37e1010" position="anchor"/></supplementary-material></sec></body><back><ack id="S13"><p>This study is supported in part by the NIH Pharmacogenomics Research Network (PGRN) RNA Sequencing Project and grants U01GM61390, HL65962, U19HL069757, R01GM094418 and U01GM092666. AC was supported by U01GM61390 and GM007175. CEF was supported by the Department of Defense (DoD) through the National Defense Science &#x00026; Engineering Graduate Fellowship (NDSEG) Program. SEB received funding from Tata Consultancy Services.</p></ack><fn-group><fn id="FN3" fn-type="conflict"><p><bold>Conflict of Interest Statement</bold></p><p>The authors declare no conflict of interest.</p></fn><fn id="FN4"><p><xref rid="SD1" ref-type="supplementary-material">Supplementary information</xref> is available at The Pharmacogenomics Journal&#x02019;s website.</p></fn></fn-group><ref-list><p id="P29">Uncategorized References</p><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name><name><surname>Weinshilboum</surname><given-names>RM</given-names></name></person-group><article-title>Genomics and drug response</article-title><source>The New England journal of medicine</source><year>2011</year><volume>364</volume><issue>12</issue><fpage>1144</fpage><lpage>1153</lpage><pub-id pub-id-type="pmid">21428770</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name></person-group><article-title>Pharmacogenomics--drug disposition, drug targets, and side effects</article-title><source>The New England journal of medicine</source><year>2003</year><volume>348</volume><issue>6</issue><fpage>538</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">12571262</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>S</given-names></name><name><surname>Syed</surname><given-names>BA</given-names></name></person-group><article-title>Commercial prospects for genomic sequencing technologies</article-title><source>Nature reviews Drug discovery</source><year>2013</year><volume>12</volume><issue>5</issue><fpage>341</fpage><lpage>342</lpage></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RP</given-names></name><name><surname>Lam</surname><given-names>ET</given-names></name><name><surname>Markova</surname><given-names>S</given-names></name><name><surname>Yee</surname><given-names>SW</given-names></name><name><surname>Ahituv</surname><given-names>N</given-names></name></person-group><article-title>Pharmacogene regulatory elements: from discovery to applications</article-title><source>Genome medicine</source><year>2012</year><volume>4</volume><issue>5</issue><fpage>45</fpage><pub-id pub-id-type="pmid">22630332</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dijk</surname><given-names>EL</given-names></name><name><surname>Auger</surname><given-names>H</given-names></name><name><surname>Jaszczyszyn</surname><given-names>Y</given-names></name><name><surname>Thermes</surname><given-names>C</given-names></name></person-group><article-title>Ten years of next-generation sequencing technology</article-title><source>Trends in genetics : TIG</source><year>2014</year><volume>30</volume><issue>9</issue><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">25108476</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Goff</surname><given-names>L</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kelley</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title><source>Nature protocols</source><year>2012</year><volume>7</volume><issue>3</issue><fpage>562</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">22383036</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>Differential expression analysis for sequence count data</article-title><source>Genome biology</source><year>2010</year><volume>11</volume><issue>10</issue><fpage>R106</fpage><pub-id pub-id-type="pmid">20979621</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Reyes</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>Detecting differential usage of exons from RNA-seq data</article-title><source>Genome research</source><year>2012</year><volume>22</volume><issue>10</issue><fpage>2008</fpage><lpage>2017</lpage><pub-id pub-id-type="pmid">22722343</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>ET</given-names></name><name><surname>Airoldi</surname><given-names>EM</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name></person-group><article-title>Analysis and design of RNA sequencing experiments for identifying isoform regulation</article-title><source>Nature methods</source><year>2010</year><volume>7</volume><issue>12</issue><fpage>1009</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">21057496</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>AN</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Duff</surname><given-names>MO</given-names></name><name><surname>Hansen</surname><given-names>KD</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name><etal/></person-group><article-title>Conservation of an RNA regulatory map between Drosophila and mammals</article-title><source>Genome research</source><year>2011</year><volume>21</volume><issue>2</issue><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">20921232</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JJ</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name><name><surname>Ginsburg</surname><given-names>GS</given-names></name></person-group><article-title>Genomic medicine: a decade of successes, challenges, and opportunities</article-title><source>Science translational medicine</source><year>2013</year><volume>5</volume><issue>189</issue><fpage>189sr184</fpage></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><article-title>The Genotype-Tissue Expression (GTEx) project</article-title><source>Nature genetics</source><year>2013</year><volume>45</volume><issue>6</issue><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">23715323</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrow</surname><given-names>J</given-names></name><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>JM</given-names></name><name><surname>Tapanari</surname><given-names>E</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Kokocinski</surname><given-names>F</given-names></name><etal/></person-group><article-title>GENCODE: the reference human genome annotation for The ENCODE Project</article-title><source>Genome research</source><year>2012</year><volume>22</volume><issue>9</issue><fpage>1760</fpage><lpage>1774</lpage><pub-id pub-id-type="pmid">22955987</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>L</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Janisch</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>M</given-names></name><name><surname>Ramirez</surname><given-names>J</given-names></name><name><surname>Karrison</surname><given-names>T</given-names></name><etal/></person-group><article-title>UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity</article-title><source>The pharmacogenomics journal</source><year>2002</year><volume>2</volume><issue>1</issue><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">11990381</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tukey</surname><given-names>RH</given-names></name><name><surname>Strassburg</surname><given-names>CP</given-names></name><name><surname>Mackenzie</surname><given-names>PI</given-names></name></person-group><article-title>Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity</article-title><source>Molecular pharmacology</source><year>2002</year><volume>62</volume><issue>3</issue><fpage>446</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">12181419</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Poi</surname><given-names>MJ</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Gaedigk</surname><given-names>A</given-names></name><name><surname>Leeder</surname><given-names>JS</given-names></name><name><surname>Sadee</surname><given-names>W</given-names></name></person-group><article-title>Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity</article-title><source>Human molecular genetics</source><year>2014</year><volume>23</volume><issue>1</issue><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">23985325</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>ZX</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Transcriptome landscape of the human placenta</article-title><source>BMC genomics</source><year>2012</year><volume>13</volume><fpage>115</fpage><pub-id pub-id-type="pmid">22448651</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>MH</given-names></name><name><surname>Grant</surname><given-names>GR</given-names></name><name><surname>White</surname><given-names>JA</given-names></name><name><surname>Sousa</surname><given-names>ME</given-names></name><name><surname>Consugar</surname><given-names>MB</given-names></name><name><surname>Pierce</surname><given-names>EA</given-names></name></person-group><article-title>Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3. 5 Mb of novel transcribed sequence via significant alternative splicing and novel genes</article-title><source>BMC genomics</source><year>2013</year><volume>14</volume><issue>1</issue><fpage>486</fpage><pub-id pub-id-type="pmid">23865674</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>McCue</surname><given-names>K</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Wold</surname><given-names>B</given-names></name></person-group><article-title>Mapping and quantifying mammalian transcriptomes by RNA-Seq</article-title><source>Nature methods</source><year>2008</year><volume>5</volume><issue>7</issue><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">18516045</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>HA</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Goosen</surname><given-names>TC</given-names></name><name><surname>Jones</surname><given-names>HM</given-names></name><name><surname>El-Kattan</surname><given-names>AF</given-names></name><name><surname>Gosset</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond</article-title><source>Expert opinion on drug metabolism &#x00026; toxicology</source><year>2013</year><volume>9</volume><issue>4</issue><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">23331046</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>A</given-names></name><name><surname>Moorthy</surname><given-names>B</given-names></name><name><surname>Ghose</surname><given-names>R</given-names></name></person-group><article-title>Drug disposition in pathophysiological conditions</article-title><source>Current drug metabolism</source><year>2012</year><volume>13</volume><issue>9</issue><fpage>1327</fpage><lpage>1344</lpage><pub-id pub-id-type="pmid">22746301</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masereeuw</surname><given-names>R</given-names></name><name><surname>Russel</surname><given-names>FG</given-names></name></person-group><article-title>Therapeutic implications of renal anionic drug transporters</article-title><source>Pharmacology &#x00026; therapeutics</source><year>2010</year><volume>126</volume><issue>2</issue><fpage>200</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">20227439</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Varma</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name><name><surname>Stephens</surname><given-names>JC</given-names></name><name><surname>Kimoto</surname><given-names>E</given-names></name><name><surname>El-Kattan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development</article-title><source>Expert opinion on drug metabolism &#x00026; toxicology</source><year>2012</year><volume>8</volume><issue>6</issue><fpage>723</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">22509796</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RS</given-names></name><name><surname>Duan</surname><given-names>S</given-names></name><name><surname>Kistner</surname><given-names>EO</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Bleibel</surname><given-names>WK</given-names></name><name><surname>Cox</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans</article-title><source>Pharmacogenetics and genomics</source><year>2008</year><volume>18</volume><issue>6</issue><fpage>545</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">18496134</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangravite</surname><given-names>LM</given-names></name><name><surname>Engelhardt</surname><given-names>BE</given-names></name><name><surname>Medina</surname><given-names>MW</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name><name><surname>Brown</surname><given-names>CD</given-names></name><name><surname>Chasman</surname><given-names>DI</given-names></name><etal/></person-group><article-title>A statin-dependent QTL for GATM expression is associated with statin-induced myopathy</article-title><source>Nature</source><year>2013</year></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>HE</given-names></name><name><surname>Dolan</surname><given-names>ME</given-names></name></person-group><article-title>Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation</article-title><source>Pharmacogenomics</source><year>2012</year><volume>13</volume><issue>1</issue><fpage>55</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">22176622</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whirl-Carrillo</surname><given-names>M</given-names></name><name><surname>McDonagh</surname><given-names>EM</given-names></name><name><surname>Hebert</surname><given-names>JM</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Sangkuhl</surname><given-names>K</given-names></name><name><surname>Thorn</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Pharmacogenomics knowledge for personalized medicine</article-title><source>Clinical pharmacology and therapeutics</source><year>2012</year><volume>92</volume><issue>4</issue><fpage>414</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">22992668</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="book"><collab>Montreal Heart Institute Pharmacogenomics Center</collab><year>2013</year><source>PharmaADME</source></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="book"><collab>U.S. Food and Drug Admnistration</collab><year>2013</year><source>Table of Pharmacogenomic Biomarkers in Drug Labels</source></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rukov</surname><given-names>JL</given-names></name><name><surname>Wilentzik</surname><given-names>R</given-names></name><name><surname>Jaffe</surname><given-names>I</given-names></name><name><surname>Vinther</surname><given-names>J</given-names></name><name><surname>Shomron</surname><given-names>N</given-names></name></person-group><article-title>Pharmaco-miR: linking microRNAs and drug effects</article-title><source>Briefings in bioinformatics</source><year>2013</year></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanov</surname><given-names>M</given-names></name><name><surname>Kals</surname><given-names>M</given-names></name><name><surname>Kacevska</surname><given-names>M</given-names></name><name><surname>Metspalu</surname><given-names>A</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name><name><surname>Milani</surname><given-names>L</given-names></name></person-group><article-title>In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes</article-title><source>Nucleic acids research</source><year>2013</year><volume>41</volume><issue>6</issue><fpage>e72</fpage><pub-id pub-id-type="pmid">23325842</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamazon</surname><given-names>ER</given-names></name><name><surname>Skol</surname><given-names>AD</given-names></name><name><surname>Perera</surname><given-names>MA</given-names></name></person-group><article-title>The limits of genome-wide methods for pharmacogenomic testing</article-title><source>Pharmacogenetics and genomics</source><year>2012</year><volume>22</volume><issue>4</issue><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">22344246</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sissung</surname><given-names>TM</given-names></name><name><surname>English</surname><given-names>BC</given-names></name><name><surname>Venzon</surname><given-names>D</given-names></name><name><surname>Figg</surname><given-names>WD</given-names></name><name><surname>Deeken</surname><given-names>JF</given-names></name></person-group><article-title>Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform</article-title><source>Pharmacogenomics</source><year>2010</year><volume>11</volume><issue>1</issue><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">20017675</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karolchik</surname><given-names>D</given-names></name><name><surname>Barber</surname><given-names>GP</given-names></name><name><surname>Casper</surname><given-names>J</given-names></name><name><surname>Clawson</surname><given-names>H</given-names></name><name><surname>Cline</surname><given-names>MS</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><etal/></person-group><article-title>The UCSC Genome Browser database: 2014 update</article-title><source>Nucleic acids research</source><year>2014</year><volume>42</volume><issue>Database issue</issue><fpage>D764</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">24270787</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>TopHat: discovering splice junctions with RNA-Seq</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><issue>9</issue><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">19289445</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><collab>Consortium GT</collab><article-title>Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans</article-title><source>Science</source><year>2015</year><volume>348</volume><issue>6235</issue><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">25954001</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>CA</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Butler</surname><given-names>H</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Gene ontology: tool for the unification of biology. The Gene Ontology Consortium</article-title><source>Nature genetics</source><year>2000</year><volume>25</volume><issue>1</issue><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">10802651</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrissey</surname><given-names>KM</given-names></name><name><surname>Stocker</surname><given-names>SL</given-names></name><name><surname>Wittwer</surname><given-names>MB</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Giacomini</surname><given-names>KM</given-names></name></person-group><article-title>Renal transporters in drug development</article-title><source>Annual review of pharmacology and toxicology</source><year>2013</year><volume>53</volume><fpage>503</fpage><lpage>529</lpage></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rask-Andersen</surname><given-names>M</given-names></name><name><surname>Masuram</surname><given-names>S</given-names></name><name><surname>Schioth</surname><given-names>HB</given-names></name></person-group><article-title>The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication</article-title><source>Annual review of pharmacology and toxicology</source><year>2014</year><volume>54</volume><fpage>9</fpage><lpage>26</lpage></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abernethy</surname><given-names>DR</given-names></name><name><surname>Schwartz</surname><given-names>JB</given-names></name></person-group><article-title>Calcium-antagonist drugs</article-title><source>The New England journal of medicine</source><year>1999</year><volume>341</volume><issue>19</issue><fpage>1447</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">10547409</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>AL</given-names><suffix>Jr</suffix></name></person-group><article-title>Recent genetic discoveries implicating ion channels in human cardiovascular diseases</article-title><source>Current opinion in pharmacology</source><year>2014</year><volume>15</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">24721653</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshiro</surname><given-names>C</given-names></name><name><surname>Thorn</surname><given-names>CF</given-names></name><name><surname>Roden</surname><given-names>DM</given-names></name><name><surname>Klein</surname><given-names>TE</given-names></name><name><surname>Altman</surname><given-names>RB</given-names></name></person-group><article-title>KCNH2 pharmacogenomics summary</article-title><source>Pharmacogenetics and genomics</source><year>2010</year><volume>20</volume><issue>12</issue><fpage>775</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">20150828</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Shai</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>LJ</given-names></name><name><surname>Frey</surname><given-names>BJ</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name></person-group><article-title>Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing</article-title><source>Nature genetics</source><year>2008</year><volume>40</volume><issue>12</issue><fpage>1413</fpage><lpage>1415</lpage><pub-id pub-id-type="pmid">18978789</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sultan</surname><given-names>M</given-names></name><name><surname>Schulz</surname><given-names>MH</given-names></name><name><surname>Richard</surname><given-names>H</given-names></name><name><surname>Magen</surname><given-names>A</given-names></name><name><surname>Klingenhoff</surname><given-names>A</given-names></name><name><surname>Scherf</surname><given-names>M</given-names></name><etal/></person-group><article-title>A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome</article-title><source>Science</source><year>2008</year><volume>321</volume><issue>5891</issue><fpage>956</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">18599741</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Jia</surname><given-names>C</given-names></name><name><surname>Kazmierkiewicz</surname><given-names>KL</given-names></name><name><surname>Bowman</surname><given-names>AS</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Comprehensive analysis of gene expression in human retina and supporting tissues</article-title><source>Human molecular genetics</source><year>2014</year><volume>23</volume><issue>15</issue><fpage>4001</fpage><lpage>4014</lpage><pub-id pub-id-type="pmid">24634144</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Papp</surname><given-names>AC</given-names></name><name><surname>Sanford</surname><given-names>JC</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Parvin</surname><given-names>JD</given-names></name><name><surname>Sadee</surname><given-names>W</given-names></name></person-group><article-title>Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver</article-title><source>Pharmacogenetics and genomics</source><year>2013</year><volume>23</volume><issue>5</issue><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">23492907</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Hallstrom</surname><given-names>BM</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Kampf</surname><given-names>C</given-names></name><name><surname>Djureinovic</surname><given-names>D</given-names></name><name><surname>Odeberg</surname><given-names>J</given-names></name><etal/></person-group><article-title>Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics</article-title><source>Molecular &#x00026; cellular proteomics : MCP</source><year>2014</year><volume>13</volume><issue>2</issue><fpage>397</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">24309898</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gremel</surname><given-names>G</given-names></name><name><surname>Wanders</surname><given-names>A</given-names></name><name><surname>Cedernaes</surname><given-names>J</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Hallstrom</surname><given-names>B</given-names></name><name><surname>Edlund</surname><given-names>K</given-names></name><etal/></person-group><article-title>The human gastrointestinal tract-specific transcriptome and proteome as defined by RNA sequencing and antibody-based profiling</article-title><source>Journal of gastroenterology</source><year>2014</year></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YS</given-names></name><name><surname>Dusting</surname><given-names>GJ</given-names></name><name><surname>Stubbs</surname><given-names>S</given-names></name><name><surname>Arunothayaraj</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>XL</given-names></name><name><surname>Collas</surname><given-names>P</given-names></name><etal/></person-group><article-title>Differentiation of human adipose-derived stem cells into beating cardiomyocytes</article-title><source>Journal of cellular and molecular medicine</source><year>2010</year><volume>14</volume><issue>4</issue><fpage>878</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">20070436</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Planat-Benard</surname><given-names>V</given-names></name><name><surname>Menard</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>M</given-names></name><name><surname>Puceat</surname><given-names>M</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Garcia-Verdugo</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells</article-title><source>Circulation research</source><year>2004</year><volume>94</volume><issue>2</issue><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">14656930</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makita</surname><given-names>N</given-names></name><name><surname>Horie</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Ai</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Yokoi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation</article-title><source>Circulation</source><year>2002</year><volume>106</volume><issue>10</issue><fpage>1269</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">12208804</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuraih</surname><given-names>M</given-names></name><name><surname>Ai</surname><given-names>T</given-names></name><name><surname>Vatta</surname><given-names>M</given-names></name><name><surname>Sohma</surname><given-names>Y</given-names></name><name><surname>Merkle</surname><given-names>EM</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><etal/></person-group><article-title>A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents</article-title><source>Journal of cardiovascular electrophysiology</source><year>2007</year><volume>18</volume><issue>4</issue><fpage>434</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">17331104</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Green</surname><given-names>RE</given-names></name><name><surname>Brenner</surname><given-names>SE</given-names></name></person-group><article-title>Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2003</year><volume>100</volume><issue>1</issue><fpage>189</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">12502788</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cropp</surname><given-names>CD</given-names></name><name><surname>Komori</surname><given-names>T</given-names></name><name><surname>Shima</surname><given-names>JE</given-names></name><name><surname>Urban</surname><given-names>TJ</given-names></name><name><surname>Yee</surname><given-names>SW</given-names></name><name><surname>More</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP</article-title><source>Molecular pharmacology</source><year>2008</year><volume>73</volume><issue>4</issue><fpage>1151</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">18216183</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlin</surname><given-names>A</given-names></name><name><surname>Geier</surname><given-names>E</given-names></name><name><surname>Stocker</surname><given-names>SL</given-names></name><name><surname>Cropp</surname><given-names>CD</given-names></name><name><surname>Grigorenko</surname><given-names>E</given-names></name><name><surname>Bloomer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures</article-title><source>Molecular pharmaceutics</source><year>2013</year><volume>10</volume><issue>2</issue><fpage>650</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">23268600</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>R</given-names></name><name><surname>Ohshiro</surname><given-names>N</given-names></name><name><surname>Ohbayashi</surname><given-names>M</given-names></name><name><surname>Kohyama</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver</article-title><source>Drug metabolism and disposition: the biological fate of chemicals</source><year>2005</year><volume>33</volume><issue>5</issue><fpage>619</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">15708966</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Ohshiro</surname><given-names>N</given-names></name><name><surname>Sakai</surname><given-names>R</given-names></name><name><surname>Ohbayashi</surname><given-names>M</given-names></name><name><surname>Kohyama</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7])</article-title><source>The Journal of pharmacy and pharmacology</source><year>2005</year><volume>57</volume><issue>5</issue><fpage>573</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">15901346</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanger</surname><given-names>UM</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation</article-title><source>Pharmacology &#x00026; therapeutics</source><year>2013</year><volume>138</volume><issue>1</issue><fpage>103</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">23333322</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="book"><collab>U.S. Department of Health and Human Services FaDAF, (CDER) CfDEaR</collab><year>2012</year><source>Guidance for Industry: Drug Interaction Studies &#x02014; Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations</source></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wempe</surname><given-names>MF</given-names></name><name><surname>Lightner</surname><given-names>JW</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name><name><surname>Iwen</surname><given-names>TJ</given-names></name><name><surname>Rice</surname><given-names>PJ</given-names></name><name><surname>Wakui</surname><given-names>S</given-names></name><etal/></person-group><article-title>Potent human uric acid transporter 1 inhibitors: in vitro and in vivo metabolism and pharmacokinetic studies</article-title><source>Drug design, development and therapy</source><year>2012</year><volume>6</volume><fpage>323</fpage><lpage>339</lpage></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name><name><surname>Peck</surname><given-names>D</given-names></name><name><surname>Modell</surname><given-names>JW</given-names></name><name><surname>Blat</surname><given-names>IC</given-names></name><name><surname>Wrobel</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease</article-title><source>Science</source><year>2006</year><volume>313</volume><issue>5795</issue><fpage>1929</fpage><lpage>1935</lpage><pub-id pub-id-type="pmid">17008526</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoemaker</surname><given-names>RH</given-names></name></person-group><article-title>The NCI60 human tumour cell line anticancer drug screen</article-title><source>Nature reviews Cancer</source><year>2006</year><volume>6</volume><issue>10</issue><fpage>813</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">16990858</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wernicke</surname><given-names>C</given-names></name><name><surname>Hellmann</surname><given-names>J</given-names></name><name><surname>Finckh</surname><given-names>U</given-names></name><name><surname>Rommelspacher</surname><given-names>H</given-names></name></person-group><article-title>Chronic ethanol exposure changes dopamine D2 receptor splicing during retinoic acid-induced differentiation of human SH-SY5Y cells</article-title><source>Pharmacological reports : PR</source><year>2010</year><volume>62</volume><issue>4</issue><fpage>649</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">20885005</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>MW</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Naidoo</surname><given-names>D</given-names></name><name><surname>Rudel</surname><given-names>LL</given-names></name><name><surname>Temel</surname><given-names>RE</given-names></name><name><surname>McDaniel</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake</article-title><source>PloS one</source><year>2011</year><volume>6</volume><issue>4</issue><fpage>e19420</fpage><pub-id pub-id-type="pmid">21559365</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solier</surname><given-names>S</given-names></name><name><surname>Barb</surname><given-names>J</given-names></name><name><surname>Zeeberg</surname><given-names>BR</given-names></name><name><surname>Varma</surname><given-names>S</given-names></name><name><surname>Ryan</surname><given-names>MC</given-names></name><name><surname>Kohn</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors</article-title><source>Cancer research</source><year>2010</year><volume>70</volume><issue>20</issue><fpage>8055</fpage><lpage>8065</lpage><pub-id pub-id-type="pmid">20817775</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stormo</surname><given-names>C</given-names></name><name><surname>Kringen</surname><given-names>MK</given-names></name><name><surname>Lyle</surname><given-names>R</given-names></name><name><surname>Olstad</surname><given-names>OK</given-names></name><name><surname>Sachse</surname><given-names>D</given-names></name><name><surname>Berg</surname><given-names>JP</given-names></name><etal/></person-group><article-title>RNA-Sequencing Analysis of HepG2 Cells Treated with Atorvastatin</article-title><source>PloS one</source><year>2014</year><volume>9</volume><issue>8</issue><fpage>e105836</fpage><pub-id pub-id-type="pmid">25153832</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivarelli</surname><given-names>S</given-names></name><name><surname>Lenzken</surname><given-names>SC</given-names></name><name><surname>Ruepp</surname><given-names>MD</given-names></name><name><surname>Ranzini</surname><given-names>F</given-names></name><name><surname>Maffioletti</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>R</given-names></name><etal/></person-group><article-title>Paraquat modulates alternative pre-mRNA splicing by modifying the intracellular distribution of SRPK2</article-title><source>PloS one</source><year>2013</year><volume>8</volume><issue>4</issue><fpage>e61980</fpage><pub-id pub-id-type="pmid">23613995</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitney</surname><given-names>AR</given-names></name><name><surname>Diehn</surname><given-names>M</given-names></name><name><surname>Popper</surname><given-names>SJ</given-names></name><name><surname>Alizadeh</surname><given-names>AA</given-names></name><name><surname>Boldrick</surname><given-names>JC</given-names></name><name><surname>Relman</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Individuality and variation in gene expression patterns in human blood</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2003</year><volume>100</volume><issue>4</issue><fpage>1896</fpage><lpage>1901</lpage><pub-id pub-id-type="pmid">12578971</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schadt</surname><given-names>EE</given-names></name><name><surname>Molony</surname><given-names>C</given-names></name><name><surname>Chudin</surname><given-names>E</given-names></name><name><surname>Hao</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Lum</surname><given-names>PY</given-names></name><etal/></person-group><article-title>Mapping the genetic architecture of gene expression in human liver</article-title><source>PLoS biology</source><year>2008</year><volume>6</volume><issue>5</issue><fpage>e107</fpage><pub-id pub-id-type="pmid">18462017</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daly</surname><given-names>AK</given-names></name></person-group><article-title>Using genome-wide association studies to identify genes important in serious adverse drug reactions</article-title><source>Annual review of pharmacology and toxicology</source><year>2012</year><volume>52</volume><fpage>21</fpage><lpage>35</lpage></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daly</surname><given-names>AK</given-names></name></person-group><article-title>Pharmacogenomics of adverse drug reactions</article-title><source>Genome medicine</source><year>2013</year><volume>5</volume><issue>1</issue><fpage>5</fpage><pub-id pub-id-type="pmid">23360680</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrie</surname><given-names>ES</given-names></name><name><surname>Smith</surname><given-names>RM</given-names></name><name><surname>Sanford</surname><given-names>JC</given-names></name><name><surname>Sadee</surname><given-names>W</given-names></name></person-group><article-title>mRNA transcript diversity creates new opportunities for pharmacological intervention</article-title><source>Molecular pharmacology</source><year>2012</year><volume>81</volume><issue>5</issue><fpage>620</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">22319206</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Wickramasinghe</surname><given-names>P</given-names></name><name><surname>Baubet</surname><given-names>V</given-names></name><name><surname>Showe</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Alternative transcription exceeds alternative splicing in generating the transcriptome diversity of cerebellar development</article-title><source>Genome research</source><year>2011</year><volume>21</volume><issue>8</issue><fpage>1260</fpage><lpage>1272</lpage><pub-id pub-id-type="pmid">21712398</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Warnes</surname><given-names>GR</given-names></name></person-group><source>gplots: Various R Programming Tools for Plotting Data</source><year>2015</year></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><source>ggplot2: elegant graphics for data analysis</source><publisher-name>Springer</publisher-name><publisher-loc>New York</publisher-loc><year>2009</year></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Overview of the Pharmacogenomics Research Network RNA-Seq project. 1. 389 &#x0201c;PGRN pharmacogenes&#x0201d; were selected representing genes that play a key role in drug disposition. 2. RNA from multiple samples for human liver, heart, kidney, adipose tissue, and lymphoblastoid cell lines was collected. 3. cDNA libraries were prepared from these samples and sequenced using an Illumina HiSeq 2000. 4. Rigorous pre- and post- alignment quality control procedures were applied to the data. 5. Gene expression was quantified and splicing events identified for the PGRN pharmacogenes across samples and tissue types. This information is provided as a resource to the pharmacogenomics community.</p></caption><graphic xlink:href="nihms738441f1"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><bold>(A)</bold> Heatmap of the 389 PGRN pharmacogenes&#x02019; expression (FPKM) across 90 samples. Samples are arranged horizontally, grouped by tissue. Pharmacogenes are arranged vertically, grouped by clusters identified by <italic>K</italic>-means clustering; clusters are indicated by colors along the left side of the heatmap. Selected clusters show (<bold>B</bold>) genes expressed at low levels across all samples (<italic>ABCB5, ABCC12, ABCC8, ADH7, ADRB3, ALDH3A1, BDNF, CACNA1S, CFTR, CHRM3, CHST13, CHST4, CHST5, CHST6, CHST8, CRHR1, CYP11B1, CYP11B2, CYP26A1, CYP26C1, CYP2A13, CYP2F1, CYP2S1, CYP4F8, CYP4Z1, CYP7A1, DRD1, DRD2, DRD3, DRD4, DRD5, ESR2, FMO6P, GNB3, GRM3, GSTA3, GSTA5, GSTT2, HTR1A, HTR2A, IL28B, KCNE2, MMP3, OPRM1, P2RY1, PNMT, PRSS53, RYR1, SCN3B, SLC10A2, SLC22A13, SLC22A14, SLC22A16, SLC22A4, SLC28A2, SLC28A3, SLC6A3, SLC6A4, SLCO1A2, SLCO6A1, SULT1A3, SULT4A1, TPH1, TPH2, TPSG1, UGT1A10, UGT1A5, UGT1A8, UGT2B11, UGT2B28)</italic> (<bold>C)</bold> genes highly expressed across all samples (<italic>ADD1, ADH5, ALDH2, CYB5A, CYB5R3, GSTK1, GSTO1, GSTP1, HLA-B, RPL13, SOD2</italic>) or genes expressed at higher levels in (<bold>D</bold>) liver (<italic>ABCB4, ABCC2, ADH1A, ADH4, APOA4, APOB, CYP2A6, CYP2B6, CYP2C18, CYP2C8, CYP2C9, CYP2D6, CYP2J2, CYP3A4, CYP3A5, CYP4F11, CYP8B1, F2, F5, MAT1A, NAT2, PON1, PON3, SERPINA7, SLC22A1, SLCO1B1, SLCO1B3, SULT2A1, UGT1A1, UGT1A4, UGT2B10, UGT2B15, UGT2B4)</italic>, (<bold>E</bold>) kidney (<italic>ABP1, FMO1, GSTA2, GSTO2, HSD11B2, SLC13A1, SLC13A3, SLC22A11, SLC22A12, SLC22A2, SLC22A6, SLC22A8, SULT1C2, UGT8</italic>), or (<bold>F</bold>) heart (<italic>ADRB1, CACNA1C, KCNH2, NPPB, RYR2, SCN5A</italic>). Gene names are listed in order from top to bottom in each cluster in the figure. Plot drawn using R package gplots. <sup><xref rid="R74" ref-type="bibr">74</xref></sup></p></caption><graphic xlink:href="nihms738441f2"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Gene expression (FPKM) by sample across each tissue type and LCLs for selected cytochrome P450 (CYP) enzymes, solute carrier family (SLC) transporters, and other pharmacogenes discussed in this article from subsampled data (18 samples per tissue type, 20 million reads per sample). The black dot indicates median FPKM per gene and tissue type. See <xref rid="SD2" ref-type="supplementary-material">Supplemental Figure 3</xref> for plots for all pharmacogenes. Plots drawn using R package ggplot2.<sup><xref rid="R75" ref-type="bibr">75</xref></sup></p></caption><graphic xlink:href="nihms738441f3"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>(<bold>A</bold>) Splice events in PGRN pharmacogenes with PSI (percent spliced in) &#x02265;5 and coverage &#x02265;1 reads/100bp in at least one sample of one tissue and no coverage in any of the four other tissues. (<bold>B</bold>) Splice events in pharmacogenes not present in current gene annotations with coverage &#x02265;5 reads/100bp in at least one sample. These splice events were identified in 68, 31, 18, 16, and 10 pharmacogenes in liver, kidney, heart, adipose tissue and LCLs respectively. (<bold>C</bold>) An alternative last exon in <italic>SLC22A7</italic>, not previously annotated, was observed in liver samples and would alter the C-terminal end of the protein. Chart: fraction of transcripts from <italic>SLC22A7</italic> that contain the novel (white) or known (black) splice event in each liver sample. Inset: reads crossing the alternative junctions in a liver sample. (<bold>D</bold>) A novel alternative 3&#x02032; splice site in <italic>SCN5A</italic> was identified that results in an 83-base deletion of the coding sequence of <italic>SCN5A</italic>, creating a premature stop codon expected to trigger nonsense-mediated mRNA decay. Chart: fraction of transcripts from <italic>SCN5A</italic> that contain the novel (white) or known (black) splice event in each heart sample.</p></caption><graphic xlink:href="nihms738441f4"/></fig></floats-group></article>